Condition: Relapsed and/or Refractory Multiple Myeloma (RRMM) · Sponsor: Regeneron Pharmaceuticals
This study is researching a drug called linvoseltamab (also called "study drug") either given alone or in combination with another anti-myeloma drug called carfilzomib, compared to several standard treatments for progressive Multiple Myeloma (MM) after at least 1 but no more than 3 prior therapies. The aim of this study is to see if the safety and efficacy of linvoseltamab alone or in combination with carfilzomib can deliver better outcomes (deeper and longer responses that help extend life) than standard treatment options. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
This description comes directly from the study's public registry record.
Clinical Trials Administrator · 844-734-6643 · clinicaltrials@regeneron.com
Always discuss trial participation with your own doctor first.
| Emory Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| OhioHealth | Columbus, Ohio, United States | Recruiting |
| University of Texas Health Science Center, Houston | Houston, Texas, United States | Recruiting |
| Mater Misericordiae Ltd | Brisbane, Queensland, Australia | Recruiting |
| Gold Coast Hospital and Health Service | Southport, Queensland, Australia | Recruiting |
| Alfred Hospital | Melbourne, Victoria, Australia | Recruiting |
| Chonnam National University Hwasun Hospital | Hwasun, Jeollanam-do, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Severance Hospital; Division of Hematology | Seoul, South Korea | Recruiting |
| Asan Medical Center | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07222761